First linevsdelayed transplantation in myeloma: Certainties and controversies
Open Access
- 1 January 2016
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Transplantation
- Vol. 6 (2), 321-330
- https://doi.org/10.5500/wjt.v6.i2.321
Abstract
Since the middle of 1990s autologous stem cell transplantation has been the cornerstone for the treatment of young patients with multiple myeloma (MM). In the last decade the introduction of novel agents such as immunomodulatory drugs (IMiDs) and proteasome inhibitors (PI), has dramatically changed the therapeutic scenario of this yet incurable disease. Due to the impressive results achieved with IMiDs and PI both in terms of response rates and in terms of progression free and overall survival, and to the toxicity linked to high dose therapy and autologous stem cell transplantation (ASCT), a burning question nowadays is whether all young patients should be offered autotransplantation up front or if this should be reserved for the time of relapse. This article provides a review of the data available regarding ASCT in MM and of the current opinion of the scientific community regarding its optimal timing.Keywords
This publication has 71 references indexed in Scilit:
- Salvage Second Hematopoietic Cell Transplantation in MyelomaTransplantation and Cellular Therapy, 2013
- Approach to the treatment of multiple myeloma: a clash of philosophiesBlood, 2011
- Early versus delayed autologous transplantation after immunomodulatory agents‐based induction therapy in patients with newly diagnosed multiple myelomaCancer, 2011
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationBlood, 2011
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005